Drug Shortage Report for BLEOMYCIN FOR INJECTION
| Report ID | 152009 |
| Drug Identification Number | 02265982 |
| Brand name | BLEOMYCIN FOR INJECTION |
| Common or Proper name | Bleomycin for Injection, 15 Units, SD Vial, 10 mL |
| Company Name | FRESENIUS KABI CANADA LTD |
| Market Status | MARKETED |
| Active Ingredient(s) | BLEOMYCIN |
| Strength(s) | 15UNIT |
| Dosage form(s) | POWDER FOR SOLUTION |
| Route of administration | SUBCUTANEOUS INTRAVENOUS INTRAPLEURAL INTRAMUSCULAR INTRAPLEURAL SUBCUTANEOUS INTRAVENOUS INTRAMUSCULAR |
| Packaging size | 10 mL |
| ATC code | L01DC |
| ATC description | CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES |
| Reason for shortage | Disruption of the manufacture of the drug. |
| Anticipated start date | 2022-02-02 |
| Actual start date | |
| Estimated end date | 2022-04-01 |
| Actual end date | 2022-04-01 |
| Shortage status | Resolved |
| Updated date | 2022-04-13 |
| Company comments | Fresenius Kabi Canada regrets to advise that due to a production delay, we will be encountering a supply interruption on our Bleomycin for Injection, 15 Units, SD Vial, 10 mL effective February 2, 2022 until March 6, 2022. Pfizer is an alternate supplier of Bleomycin for Injection and have been informed of our impending supply interruption. |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 165 GALAXY BLVD, SUITE 100 TORONTO, ONTARIO CANADA M9W 0C8 |
| Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v7 | 2022-04-13 | French | Compare |
| v6 | 2022-04-13 | English | Compare |
| v5 | 2022-02-28 | French | Compare |
| v4 | 2022-02-28 | English | Compare |
| v3 | 2022-02-03 | English | Compare |
| v2 | 2021-12-31 | French | Compare |
| v1 | 2021-12-31 | English | Compare |
Showing 1 to 7 of 7